MASH symptoms

Signs of MASH can be difficult to identify but there are some
symptoms and risk factors of which to be aware

Common symptoms of fatty liver disease and MASH

People living with MASH often have few or no symptoms, especially in its early stages. People with MASH usually report feeling non-specific symptoms that can easily be mistaken for other conditions. 

 

These symptoms may include: 

 

  • Abdominal pain, usually in the upper right side (or discomfort in the upper right belly area)
  • Back pain 
  • Fatigue 
  • Weakness 
  • Loss of appetite 
  • Nausea 
  • Swelling of the leg 

 

Because symptoms are often non-specific, it can be challenging to recognize and diagnose MASH. If you think you might be at risk of MASH or are already showing symptoms, it's important to contact your healthcare provider right away. 

 

Under the guidance of your healthcare professional, you will likely undergo a number of simple imaging and blood tests to assess your risk and confirm the diagnosis and severity. 

 

In case these tests are inconsistent a liver biopsy may be needed to assess the severity of the disease1.

MASH and MASLD are updated terms for conditions previously known as NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease). Similarly, "steatotic liver disease" is the current term for what was once called "fatty liver disease".

How is MASH diagnosed?

Testing for MASH often begins with simple imaging and blood tests, which are typically sufficient to determine the diagnosis.

MASH causes

MASH impacts a growing number of people worldwide2, with more than 250 million people living with the condition3.

 

Scientists do not fully understand what causes MASLD (the early stage of MASH) or why some people develop MASH and others do not. Research suggests that environmental factors, family history, and genetics may also play a role4.

 

MASH is often found to coexist in people who also live with obesity or Type 2 Diabetes5. More than one in three people living with obesity also live with MASH, and one in three people living with Type 2 Diabetes also live with MASH6. Other common risk factors include dyslipidemia7 and hypertension8.

 

If you are living with obesity, Type 2 Diabetes, dyslipidemia or hypertension you could be at risk of developing MASH, and your healthcare provider should monitor your risk of MASH as part of your regular follow-up.

How do you treat MASH? 

While treatment options remain limited, the first step to help slow the progression of MASH and reduce liver scarring is to eat a healthy diet, maintain an active lifestyle, and manage any risk factors9

MASH risk factors 

Both MASLD and MASH have being linked to10:

 

  • Poor diet
  • Inactive life-style
  • Obesity 
  • Type 2 Diabetes 
  • Insulin resistance 
  • High cholesterol 
  • High blood pressure  
  • Hypothyroidism
  • Sleep apnea 

 

If you are living with one or more of the above conditions, it’s important to speak with your healthcare provider about MASH.

Related articles

  1. ILKe Nalbantoglu, Role of liver biopsy in nonalcoholic fatty liver disease: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112884/
Last accessed: September 2024
  2. Bashar Sharma, Non-alcoholic steatohepatitis: 
https://www.ncbi.nlm.nih.gov/books/NBK470243/
Last accessed: September 2024
  3. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-1347: 
https://pubmed.ncbi.nlm.nih.gov/36626630/
Last accessed: September 2024
  4. Oriol Juanola, Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors: 
https://www.mdpi.com/1660-4601/18/10/5227
Last accessed: September 2024
  5. Sofiya Gancheva, Diabetes as a risk factor for MASH progression: https://www.sciencedirect.com/science/article/pii/S0168822724007563
Last accessed: October 2024
  6. Nikita Mittal, A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States: https://pubmed.ncbi.nlm.nih.gov/38586922/
Last accessed: October 2024
  7. Qing-Quing Zhang, Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542078/
Last accessed: September 2024
  8. Chongyang Ma, The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806441/
Last accessed: September 2024
  9. Kate Hallsworth, Lifestyle modification in NAFLD/NASH: Facts and figures: https://www.sciencedirect.com/science/article/pii/S2589555919301302
Last accessed: September 2024
  10. National Guideline Centre, Risk Factors for NAFLD: 
https://www.ncbi.nlm.nih.gov/books/NBK384735/
Last accessed: September 2024